Pharmaceutical giant Elan is to receive $55m (€45.07m) from British biotech firm Vernalis for the North American commericialisation rights to migraine treatment Frova.
Vernalis, formed from a merger of RiboTargets and Vernalis Group, changed its name to Vernalis in 2003.
CONNECT WITH US TODAY
Be the first to know the latest news and updates
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpNewsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Newsletter
Get a lunch briefing straight to your inbox at noon daily. Also be the first to know with our occasional Breaking News emails.
Monday, August 10, 2026 - 10:00 PM
Monday, August 10, 2026 - 10:00 PM
Monday, August 10, 2026 - 1:00 PM
